<SEC-DOCUMENT>0001062822-24-000029.txt : 20240510
<SEC-HEADER>0001062822-24-000029.hdr.sgml : 20240510
<ACCEPTANCE-DATETIME>20240510161554
ACCESSION NUMBER:		0001062822-24-000029
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240510
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240510
DATE AS OF CHANGE:		20240510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		24935086

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrx-20240510.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:91339ed7-c34d-4130-91e5-d6460f07f312,g:e06e91d0-3e8e-4e3e-af2a-9ce6cb89d8b6,d:5c421e7f6a1b480792ba7a71d761e614-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20240510</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-23">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20240510.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-10</xbrli:startDate><xbrli:endDate>2024-05-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5c421e7f6a1b480792ba7a71d761e614_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 10, 2024</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"/><td style="width:32.755%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.091%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30111</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2445 Technology Forest Blvd., 11th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">281</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">863-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:34.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.904%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-18">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-19">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div id="i5c421e7f6a1b480792ba7a71d761e614_115"></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 3.02&#160;&#160;&#160;&#160;Unregistered Sale of Equity Securities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 10, 2024, each outstanding share of our Series A Convertible Preferred Stock, par value $0.01 per share (the &#8220;Preferred Stock&#8221;), was converted (the &#8220;conversion&#8221;) into 50 shares of our common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;).  2,304,147 shares of Preferred Stock were outstanding immediately prior to the conversion, and 115,207,350 shares of Common Stock were issued as a result of the conversion.  The Preferred Stock was sold in a previously announced private placement pursuant to a Preferred Stock Purchase Agreement at a price of $108.50 per share.  The shares of Common Stock issued upon the conversion were issued pursuant to the terms of the Certificate of Designations of Series A Convertible Preferred Stock, which, among other things, provided for the automatic conversion of the Preferred Stock upon the satisfaction of certain conditions without any investment decision required of the holders thereof, and thus did not constitute a &#8220;sale&#8221; within the meaning of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).  The shares of Common Stock issued pursuant to the conversion were issued in reliance upon an exemption from registration set forth in Section 3(a)(9) of the Securities Act, as the securities were issued to only holders of Preferred Stock and no commission or other remuneration was paid or given directly or indirectly for the solicitation of the conversion.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i5c421e7f6a1b480792ba7a71d761e614_7"></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 5.03&#160;&#160;&#160;&#160;Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 10, 2024, we filed a Sixth Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, which became effective on the filing date. The Sixth Amended and Restated Certificate of Incorporation increases the number of shares of our authorized Common Stock from 300,000,000 to 450,000,000.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The foregoing summary does not purport to be complete and is qualified in its entirety by our Sixth Amended and Restated Certificate of Incorporation, a copy of which is attached to this report as Exhibit 3.1 and incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5c421e7f6a1b480792ba7a71d761e614_10"></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 5.07&#160;&#160;&#160;&#160;Submission of Matters to a Vote of Security Holders</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our annual meeting of stockholders was held on May 10, 2024 to consider and vote on the following proposals.  The voting results with respect to each matter are set forth below: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Election of Class III Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Withheld</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Broker </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Votes</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Philippe J. Amouyal</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">241,812,501</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18,607,732</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,015,729</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Lonnel Coats</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">247,448,636</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12,971,597</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,015,729</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diane E. Sullivan</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">259,435,040</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">985,193</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,015,729</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.768%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Abstain</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ratification and approval of the the Company&#8217;s Sixth Amended and Restated Certificate of Incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">160,676,391</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,433,806</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">211,035</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Abstain</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Broker </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Votes</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Advisory vote to approve the compensation paid to the Company&#8217;s named executive officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">253,593,322</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6,203,593</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">623,318</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29,015,729</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Abstain</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Ratification and approval of the appointment of Ernst &amp; Young LLP as Company's independent auditors for the fiscal year ending December&#160;31, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">286,136,766</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2,884,465</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">414,731</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div id="i5c421e7f6a1b480792ba7a71d761e614_13"></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span><br/></span></div><div style="-sec-extract:summary;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:12.202%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh31-sixthamendedandresta.htm">Sixth Amended and Restated Certificate of Incorporation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EX-104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5c421e7f6a1b480792ba7a71d761e614_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"/><td style="width:52.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   May 10, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and General Counsel</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exh31-sixthamendedandresta.htm
<DESCRIPTION>EX-3.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8020b8b2dc8d4905a4e1ee6442c0b304_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 3.1</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEXICON PHARMACEUTICALS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LEXICON PHARMACEUTICALS, INC. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), hereby certifies as follows pursuant to Sections 242 and 245 of the DGCL&#58;</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58; &#160;&#160;&#160;&#160;The name of the Corporation is &#8220;Lexicon Pharmaceuticals, Inc.&#8221; The Corporation was previously incorporated as &#8220;Lexicon Genetics Incorporated&#8221; on July 7, 1995.</font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; &#160;&#160;&#160;&#160;The current Certificate of Incorporation of the Corporation was filed in the Office of the Secretary of State of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Secretary of State</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on May 20, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIRD&#58; &#160;&#160;&#160;&#160;The Board of Directors of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in accordance with Sections 242 and 245 of the DGCL, (i) adopted and approved this Sixth Amended and Restated Certificate of Incorporation (including the amendments to the Corporation&#8217;s Certificate of Incorporation effected hereby) and (ii) proposed that the Corporation&#8217;s stockholders adopt and approve this Sixth Amended and Restated Certificate of Incorporation (including the amendments to the Corporation&#8217;s Certificate of Incorporation effected hereby).</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOURTH&#58; &#160;&#160;&#160;&#160;The holders of not less than a majority of the outstanding shares of the Corporation&#8217;s common stock, par value $.001 per share, and preferred stock, par value $0.01 per share, in accordance with Sections 242 and 245 of the DGCL, approved and adopted on behalf of the stockholders this Sixth Amended and Restated Certificate of Incorporation (including the amendments to the Corporation&#8217;s Certificate of Incorporation effected hereby).</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIFTH&#58;&#160;&#160;&#160;&#160;This Sixth Amended and Restated Certificate of Incorporation shall become effective on its filing with the Secretary of State.</font></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIXTH&#58;&#160;&#160;&#160;&#160;The current Certificate of Incorporation of the Corporation is hereby amended and restated to read in its entirety as follows&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE I</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Name</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The name of the Corporation is &#8220;Lexicon Pharmaceuticals, Inc.&#8221;</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE II</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registered Office and Registered Agent</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registered office of the Corporation in the State of Delaware is located at 251 Little Falls Drive in the City of Wilmington, County of New Castle, Zip Code 19808. The name of the registered agent of the Corporation at such address is Corporation Service Company.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE III</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purpose</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose for which the Corporation is organized is to engage in any lawful acts and activities for which corporations may be organized under the General Corporation Law of the State of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE IV</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Capitalization</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.04pt;text-decoration:underline">Authorized Capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) The total number of shares of stock that the Corporation shall have the authority to issue is 455,000,000 shares of capital stock, consisting of (i) 5,000,000 shares of preferred stock, par value $0.01 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and (ii) 450,000,000 shares of common stock, par value $0.001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Subject to the provisions of this Certificate of Incorporation and the Preferred Stock Designation (as defined below) creating any series of Preferred Stock, the Corporation may issue shares of its capital stock from time to time for such consideration (not less than the par value thereof) as may be fixed by the Board of Directors of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which is expressly authorized to fix the same in its absolute discretion subject to the foregoing conditions. Shares so issued for which the consideration shall have been paid or delivered to the Corporation shall be deemed fully paid stock and shall not be liable to any further call or assessment thereon, and the holders of such shares shall not be liable for any further payments in respect of such shares.</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The right to cumulate votes for the election of directors as provided in Section 214 of the DGCL shall not be granted and is hereby expressly denied.</font></div><div><font><br></font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Subject to Article XII, no stockholder of the Corporation shall by reason of his or her holding shares of any class of capital stock of the Corporation have any preemptive or preferential right to acquire or subscribe for any additional, unissued or treasury shares (whether now or hereafter acquired) of any class of capital stock of the Corporation now or hereafter to be authorized, or any notes, debentures, bonds or other securities convertible into or carrying any right, option or warrant to subscribe for or acquire shares of any class of capital stock of the Corporation now or hereafter to be authorized, whether or not the issuance of any such shares or such notes, debentures, bonds or other securities would adversely affect the dividends or voting or other rights of that stockholder.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) The Preferred Stock may be issued from time to time in one or more series. Authority is hereby expressly granted to and vested in the Board of Directors to authorize from time to time the issuance of Preferred Stock in one or more series. With respect to each series of Preferred Stock authorized by it, the Board of Directors shall be authorized to establish by resolution or resolutions, and by filing a certificate pursuant to applicable law of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the following to the fullest extent now or hereafter permitted by the DGCL&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the designation of such series&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the number of shares to constitute such series&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">whether such series is to have voting rights (full, special or limited) or is to be without voting rights&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">if such series is to have voting rights, whether or not such series is to be entitled to vote as a separate class either alone or together with the holders of the Common Stock or one or more other series of Preferred Stock&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the preferences and relative, participating, optional, conversion or other special rights (if any) of such series and the qualifications, limitations or restrictions (if any) with respect to such series&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the redemption rights and price(s), if any, of such series, and whether or not the shares of such series shall be subject to the operation of retirement or sinking funds to be applied to the purchase or redemption of such shares for retirement and, if such retirement or sinking funds or funds are to be established, the periodic amount thereof and the terms and provisions relative to the operation thereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the dividend rights and preferences (if any) of such series, including, without limitation, (i) the rates of dividends payable thereon, (ii) the conditions upon which and the time when such dividends are payable, (iii) whether or not such dividends shall be cumulative or noncumulative and, if cumulative, the date or dates from which such dividends shall accumulate and (iv) whether or not the payment of such dividends shall be preferred to the payment of dividends payable on the Common Stock or any other series of Preferred Stock&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the preferences (if any), and the amounts thereof, which the holders of such series shall be entitled to receive upon the voluntary or involuntary liquidation, dissolution or winding-up of, or upon any distribution of the assets of, the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">whether or not the shares of such series, at the option of the Corporation or the holders thereof or upon the happening of any specified event, shall be convertible into or exchangeable for (i) shares of Common Stock, (ii) shares of any other series of Preferred Stock or (iii) any other stock or securities of the Corporation&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">if such series is to be convertible or exchangeable, the price or prices or ratio or ratios or rate or rates at which such conversion or exchange may be made and the terms and conditions (if any) upon which such price or prices or ratio or ratios or rate or rates may be adjusted&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.34pt">such other rights, powers and preferences with respect to such series as may to the Board of Directors seem advisable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any series of Preferred Stock may vary from any other series of Preferred Stock in any or all of the foregoing respects and in any other manner.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Board of Directors may, with respect to any existing series of Preferred Stock but subject to the Preferred Stock Designation creating such series, (i) increase the number of shares of Preferred Stock designated for such series by a resolution adding to such series authorized and unissued shares of Preferred Stock not designated for any other series and (ii) decrease the number of shares of Preferred Stock designated for such series by a resolution subtracting from such series shares of Preferred Stock designated for such series (but not below the number of shares of such series then outstanding), and the shares so subtracted shall become authorized, unissued and undesignated shares of Preferred Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;No vote of the holders of the Common Stock or the Preferred Stock shall, unless otherwise expressly provided in a Preferred Stock Designation creating any series of Preferred Stock, be a prerequisite to the issuance of any shares of any series of the Preferred Stock authorized by and complying with the conditions of this Certificate of Incorporation. Shares of any series of Preferred Stock that have been authorized for issuance pursuant to this Certificate of Incorporation and that have been issued and reacquired in any manner by the Corporation (including upon conversion or exchange thereof) shall be restored to the status of authorized and unissued shares of Preferred Stock and may be reissued as part of a new series of Preferred Stock to be created by resolution or resolutions of the Board of Directors and a Preferred Stock Designation as set forth above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.03.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) The holders of shares of the Common Stock shall be entitled to vote upon all matters submitted to a vote of the common stockholders of the Corporation and shall be entitled to one vote for each share of the Common Stock held.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Subject to the prior rights and preferences (if any) applicable to shares of Preferred Stock of any series, the holders of shares of the Common Stock shall be entitled to receive such dividends (payable in cash, stock or otherwise) as may be declared thereon by the Board of Directors at any time and from time to time out of any funds of the Corporation legally available therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, after payment or provision for payment of the debts and other liabilities of the Corporation and subject to the preferential or other rights (if any) of the holders of shares of the Preferred Stock in respect thereof, the holders of shares of the Common Stock shall be entitled to receive all the remaining assets of the Corporation available for distribution to its stockholders, ratably in proportion to the number of shares of the Common Stock held by them. For purposes of this paragraph (c), a liquidation, dissolution or winding-up of the Corporation shall not be deemed to be occasioned by or to include (i) any consolidation or merger of the Corporation with or into another corporation or other entity or (ii) a sale, lease, exchange or conveyance of all or a part of the assets of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.04.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Options, Warrants, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unless otherwise expressly prohibited in the Preferred Stock Designation creating any series of Preferred Stock, the Corporation shall have authority to create and issue warrants, rights and options entitling the holders thereof to purchase from the Corporation shares of the Corporation&#8217;s capital stock of any class or series or other securities of the Corporation for such consideration and to such persons, firms or corporations as the Board of Directors, in its sole discretion, may determine, setting aside from the authorized but unissued capital stock of the Corporation the requisite number of shares for issuance upon the exercise of such warrants, rights or options. Such warrants, rights and options shall be evidenced by one or more instruments approved by the Board of Directors. The Board of Directors shall be empowered to set the exercise price, duration, time for exercise and other terms of such warrants, rights or options&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the consideration to be received for any shares of capital stock subject thereto shall not be less than the par value thereof.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE V</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Directors</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.01.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Number and Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The number of directors of the Corporation shall from time to time be fixed exclusively by the Board of Directors in accordance with, and subject to the limitations set forth in, the bylaws of the Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the Board of Directors shall at all times consist of a minimum of three and a maximum of 13 directors, subject, however, to increases above 13 directors as may be required in order to permit the holders of any series of Preferred Stock to exercise their right (if any) to elect additional directors under specified circumstances or to permit the election or appointment to the Board of Directors of the Required Director Number of Investor Designated Directors (each as defined in the Stockholders&#8217; Agreement, dated as of June 17, 2007, between Invus, L.P. and the Corporation (as amended, supplemented or otherwise modified, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stockholders&#8217; Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)) pursuant to the Stockholders&#8217; Agreement. No decrease in the number of directors shall have the effect of shortening the term of any incumbent director. Anything in this Certificate of Incorporation or the Bylaws to the contrary notwithstanding, each director shall hold office until his successor is elected and qualified or until his earlier death, resignation or removal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.02.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation of Personal Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) No person who is or was a director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director&#8217;s duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL or (iv) for any transaction from which the director derived an improper personal benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If the DGCL is hereafter amended to authorize corporate action further limiting or eliminating the personal liability of directors, then the personal liability of the directors to the Corporation or its stockholders shall be limited or eliminated to the fullest extent permitted by the DGCL, as so amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.03.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Classification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Board of Directors shall be divided into three classes designated as Class I, Class II and Class III, respectively, all as nearly equal in number as possible, with each director then in office receiving the classification to be determined with respect to such director by the Board of Directors. The initial term of office of Class I directors shall expire at the annual meeting of the Corporation&#8217;s stockholders in 2001. The initial term of office of Class II directors shall expire at the annual meeting of stockholders in 2002. The initial term of office of Class III directors shall expire at the annual meeting of stockholders in 2003. Each director elected at an annual meeting of stockholders to succeed a director whose term is then expiring shall hold office until the third annual meeting of stockholders after his election or until his successor is elected and qualified or until his earlier death, resignation or removal. Increases and decreases in the number of directors shall be apportioned among the classes of directors so that all classes will be as nearly equal in number as possible. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.04.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nomination and Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) Nominations of persons for election or reelection to the Board of Directors may be made by or at the direction of the Board of Directors. The Bylaws may set forth procedures for the nomination of persons for election or reelection to the Board of Directors and only persons who are nominated in accordance with such procedures (if any) shall be eligible for election or reelection as directors of the Corporation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that such procedures shall not infringe upon (i) the right of the Board of Directors to nominate persons for election or reelection to the Board of Directors or (ii) the rights of the holders of any class or series of Preferred Stock, voting separately by class or series, to elect additional directors under specified circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each director shall be elected in accordance with this Certificate of Incorporation, the Bylaws and applicable law. Election of directors by the Corporation&#8217;s stockholders need not be by written ballot unless the Bylaws so provide.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.05.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Removal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No director of any class may be removed before the expiration of his term of office except for cause and then only by the affirmative vote of the holders of not less than a majority in voting power of all the outstanding shares of capital stock of the Corporation entitled to vote generally in an election of directors, voting together as a single class. The Board of Directors may not remove any director, and no recommendation by the Board of Directors that a director be removed may be made to the Corporation&#8217;s stockholders unless such recommendation is set forth in a resolution adopted by the affirmative vote of not less than 66-2&#47;3% of the whole Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.06.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vacancies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) In case any vacancy shall occur on the Board of Directors because of death, resignation or removal, such vacancy may be filled only by a majority (or such higher percentage as may be specified in the Bylaws) of the directors remaining in office (though less than a quorum), or by the sole remaining director. The director so appointed shall serve for the unexpired term of his predecessor or until his successor is elected and qualified or until his earlier </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">death, resignation or removal. If there are no directors then in office, an election of directors may be held in the manner provided by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any newly-created directorship resulting from any increase in the number of directors may be filled only by a majority (or such higher percentage as may be specified in the Bylaws) of the directors then in office (though less than a quorum), or by the sole remaining director. The director so appointed shall be assigned to such class of directors as such majority of directors or the sole remaining director, as the case may be, shall determine&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that newly-created directorships shall be apportioned among the classes of directors so that all classes will be as nearly equal in number as possible. Each director so appointed shall hold office for the remaining term of the class to which he is assigned or until his successor is elected and qualified or until his earlier death, resignation or removal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Except as expressly provided in this Certificate of Incorporation or as otherwise provided by applicable law, stockholders of the Corporation shall not have the right to fill vacancies on the Board of Directors, including newly-created directorships.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.07.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subject to Rights of Holders of Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing provisions of this Article&#160;V, if the Preferred Stock Designation creating any series of Preferred Stock entitles the holders of such Preferred Stock, voting separately by class or series, to elect additional directors under specified circumstances, then all provisions of such Preferred Stock Designation relating to the nomination, election, term of office, removal, filling of vacancies and other features of such directorships shall, as to such directorships, govern and control over any conflicting provisions of this Article&#160;V, and such directors so elected need not be divided into classes pursuant to this Article&#160;V unless expressly provided by the provisions of such Preferred Stock Designation.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VI</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Bylaws</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is expressly authorized and empowered to adopt, alter, amend or repeal the Bylaws. Stockholders of the Corporation shall have the power to alter, amend, expand or repeal the Bylaws but only by the affirmative vote of the holders of not less than 66-2&#47;3% in voting power of all outstanding shares of capital stock of the Corporation entitled to vote generally at an election of directors, voting together as a single class.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VII</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Actions and Meetings of Stockholders</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.01.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Action by Written Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No action shall be taken by the stockholders of the Corporation except at an annual or special meeting of stockholders. Stockholders of the Corporation may not act by written consent in lieu of a meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.02.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a) Meetings of the stockholders of the Corporation (whether annual or special) may only be called by the Board of Directors or by such officer or officers of the Corporation as the Board of Directors may from time to time authorize to call meetings of the stockholders of the Corporation. Stockholders of the Corporation shall not be entitled to call any meeting of stockholders or to require the Board of Directors or any officer or officers of the Corporation to call a meeting of stockholders except as otherwise expressly provided in the Bylaws or in the Preferred Stock Designation creating any series of Preferred Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Stockholders of the Corporation shall not be entitled to propose business for consideration at any meeting of stockholders except as otherwise expressly provided in the Bylaws or in the Preferred Stock Designation creating any series of Preferred Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Business transacted at any special meeting of stockholders shall be limited to the purposes stated in the notice or waivers of notice of such meeting. The person presiding at a meeting of stockholders may determine whether business has been properly brought before the meeting and, if the facts so warrant, such person may refuse to transact any business at such meeting which has not been properly brought before such meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.03.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Appoint and Remove Officers, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The stockholders of the Corporation shall have no right or power to appoint or remove officers of the Corporation nor to abrogate the power of the Board of Directors to elect and remove officers of the Corporation. The stockholders of the Corporation shall have no power to appoint or remove directors as members of committees of the Board of Directors nor to abrogate the power of the Board of Directors to establish one or more such committees or the power of any such committee to exercise the powers and authority of the Board of Directors.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.04.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compromises and Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Whenever a compromise or arrangement is proposed between this corporation and its creditors or any class of them and&#47;or between this corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this corporation or of any creditor or stockholder thereof or on the application of any receiver or receivers appointed for this corporation under &#167; 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for this corporation under &#167; 279 of Title 8 of the Delaware code order a meeting of the creditors or class of creditors, and&#47;or of the stockholders or class of stockholders of this corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three fourths in value of the creditors or class of creditors, and&#47;or of the stockholders or class of stockholders of this corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or class of creditors, and&#47;or on all the stockholders or class of stockholders, of this corporation, as the case may be, and also on this corporation.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE VIII</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification of Directors and Officers</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation shall indemnify, to the fullest extent permitted by applicable law and pursuant to the Bylaws, each person who is or was a director or officer of the Corporation, and may indemnify each employee and agent of the Corporation and all other persons whom the Corporation is authorized to indemnify under the provisions of the DGCL.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE IX</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Election to be Governed by Section 203 of the DGCL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation hereby elects to be governed by Section 203 of the DGCL&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that the provisions of this Article&#160;IX shall not apply to restrict a business combination between the Corporation and an interested stockholder (as defined in Section 203 of the DGCL) of the Corporation if either (i) such business combination was approved by the Board of Directors prior to the time that such stockholder became an interested stockholder or (ii) such stockholder became an interested stockholder as a result of, and at or prior to the effective time of, a transaction which was approved by the Board of Directors prior to the time that such stockholder became an interested stockholder.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE X</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Certificate of Incorporation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation reserves the right to amend, alter, change or repeal any provisions contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by applicable law, and all rights conferred upon stockholders, directors or any other persons by or pursuant to this Certificate of Incorporation are granted subject to this reservation. Notwithstanding the foregoing or any other provision of this Certificate of Incorporation or any provision of law that might otherwise permit a lesser or no vote, the provisions of this Article&#160;X and of Articles V, VI, VII and VIII may not be repealed or amended in any respect, and no provision inconsistent with any such provision or imposing cumulative voting in the election of directors may be added to this Certificate of Incorporation, unless such action is approved by the affirmative vote of the holders of not less than 66-2&#47;3% in voting power of all outstanding shares of capital stock of the Corporation entitled to vote generally at an election of directors, voting together as a single class&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that any amendment or repeal of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or Article&#160;VIII of this Certificate of Incorporation shall not adversely affect any right or protection existing thereunder in respect of any act or omission occurring prior to such amendment or repeal and, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that no Preferred Stock Designation shall be amended after the issuance of any shares of the Series of Preferred Stock created thereby, except in accordance with the terms of such Preferred Stock Designation and the requirements of applicable law.</font></div><div style="margin-bottom:0.03pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE XI</font></div><div style="margin-bottom:9pt;margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Requirements Not Exclusive</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting requirements contained in this Certificate of Incorporation shall be in addition to the voting requirements imposed by law or by the Preferred Stock Designation creating any series of Preferred Stock.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ARTICLE XII</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Rights of Covered Stockholders</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.01.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rights to Purchase New Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. (a)&#160;Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.01(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the event that the Corporation proposes to issue New Securities, a Covered Stockholder shall have the right to purchase, in lieu of the person to whom the Corporation proposed to issue such New Securities, in accordance with paragraph (b)&#160;below, a number of New Securities equal to the product of (i)&#160;the total number or amount of New Securities which the Corporation proposes to issue at such time and (ii)&#160;a fraction, the numerator of which shall be the total number of shares of Common Stock which the Covered Stockholder beneficially owns at the relevant measurement point, and the denominator of which shall be the aggregate number of shares of Common Stock then outstanding (the number referred to in clause (ii), the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the event that the Corporation proposes to undertake an issuance of New Securities, it shall give written notice (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Issuance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of its intention to the Covered Stockholder indicating the price per New Security (or, to the extent not reasonably known to the Corporation at such time, the methodology for determining such price) and the number of New Securities to be issued by the Corporation, and describing the material terms of the New Securities and the material terms upon which the Corporation proposes to issue such New Securities. The Covered Stockholder shall have two business days from the date of receipt of the Notice of Issuance to agree to purchase all or a portion of the Covered Stockholder&#8217;s Pro Rata Share of such New Securities (as determined pursuant to paragraph (a)&#160;above) for the same consideration and otherwise upon the terms specified in the Notice of Issuance (unless better terms are provided to any other purchaser) by giving written notice to the Corporation and stating therein the quantity of New Securities to be purchased by the Covered Stockholder. If the Covered Stockholder exercises its right to purchase New Securities pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the purchase and sale of such New Securities shall close at the same time as the issuance of New Securities to the other purchaser or purchasers and, subject to the preceding sentence, shall be issued on the same terms and subject to the same conditions as applicable to the other purchaser or purchasers&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that (i)&#160;such terms and conditions applicable to the Covered Stockholder shall not include any restrictions on the transferability of such New Securities (except pursuant to applicable laws and regulations) or any standstill, voting or other restrictions, (ii)&#160;the Covered Stockholder shall not be required to make any representations and warranties except those that relate solely to the Covered Stockholder and (iii)&#160;the Covered Stockholder will not be required to undertake any indemnification obligation.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights given by the Corporation under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall terminate if unexercised within two business days after receipt of the Notice of Issuance referred to in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained herein, if (i)&#160;the price or any other material terms upon which the Corporation proposes to issue such New Securities are amended by the Corporation following the delivery to the Covered Stockholder of the Notice of Issuance or (ii)&#160;the offering of New Securities to which a Notice of Issuance relates is not completed within five&#160;business days from the delivery of such notice to the Covered Stockholder, the Covered Stockholder&#8217;s election with respect to the purchase of New Securities covered by such Notice of Issuance shall be void and the Corporation shall be obligated to deliver a new Notice of Issuance to the Covered Stockholder, and the Covered Stockholder shall be entitled to make a new election with respect to the purchase by it of New Securities covered by such notice within the two-business day period from the date of delivery of the new Notice of Issuance and otherwise in accordance with the procedure specified in the second sentence of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if  the Corporation proposes to issue New Securities in an aggregate amount of at least $25,000,000 in a Public Offering, the Notice of Issuance may, in lieu of specifying the price at which the Corporation proposes to issue New Securities  and the number of New Securities to be issued by the Corporation in such offering, provide an estimated aggregate public offering size (in dollar amount) of the New Securities (exclusive of any Overallotment Securities, as contemplated by the following paragraph) that the Corporation estimates will ultimately be issued in such offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Offering Size</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and, to the extent different from the closing price per share of the Common Stock on the Nasdaq Stock Market or the principal securities exchange on which the Common Stock is then listed on the date immediately prior to the date on which the Notice of Issuance is delivered to the Covered Stockholder pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.01(c),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an estimated public offering price per New Security (such closing price of the Common Stock or, if specified in such Issuance Notice, the estimated price per New Security so specified, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estimated Offering Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If the Covered Stockholder desires to exercise its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to such Public Offering, the Covered Stockholder shall be required to make an election with respect to the purchase, at the public offering price in such Public Offering, of a dollar amount of New Securities up to its Pro Rata Share of the Estimated Offering Size no later than two business days from the date of receipt of the Notice of Issuance (which period shall be reduced to one business day if, prior to delivery of such Notice of Issuance, such Covered Stockholder, to the extent requested by the Corporation, had not entered into a customary agreement reasonably satisfactory to the Corporation requiring that the Covered Stockholder maintain the confidentiality of the proposed Public Offering unless and until publicly announced by the Corporation)&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the Covered Stockholder&#8217;s obligation to purchase the dollar amount of New Securities subject to its election shall be conditioned upon (i)&#160;the issuance by the Corporation of New Securities in such Public Offering at an aggregate public offering </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price of at least 85% and no more than 115% of the Estimated Offering Size and (ii)&#160;the New Securities so issued being priced not higher than 15% above the Estimated Offering Price. For clarity, in the event the Covered Stockholder does not purchase the dollar amount of New Securities subject to its election in reliance upon the foregoing proviso, the Covered Stockholder shall be deemed to have chosen not to exercise its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to such Public Offering.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any Notice of Issuance provided by the Corporation to the Covered Stockholder in connection with a Public Offering may specify that the underwriters or agents in such offering shall be entitled to purchase upon exercise of an overallotment option, if any, additional New Securities in an amount up to 15% of the New Securities issued in such Public Offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Overallotment Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). If the Covered Stockholder desires to exercise its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with respect to Overallotment Securities, the Covered Stockholder shall be required to make an election with respect to the purchase of up to its Pro Rata Share of the Overallotment Securities at the same time the Covered Stockholder makes an election pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the Covered Stockholder&#8217;s obligation to purchase Overallotment Securities in accordance with its election shall be subject to the same conditions to which its obligations to purchase New Securities in the Public Offering, before giving effect to such Overallotment Securities, are subject.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a Public Offering contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is not completed within five&#160;business days following the Notice of Issuance with respect thereto, then the Corporation will be required to comply again with the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in order to avail itself of the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In case a Public Offering contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is consummated, the Covered Stockholder shall be obligated to purchase the New Securities which it has elected to purchase hereunder at the closing of such Public Offering if and to the extent the conditions to the Covered Stockholder&#8217;s obligations hereunder are met, on the same terms and subject to the same conditions that would be applicable to the underwriters in such offering&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">however,&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that (i)&#160;such terms and conditions applicable to the Covered Stockholder shall not include any restrictions on the transferability of such New Securities (except pursuant to applicable laws and regulations) or any standstill, voting or other restrictions,, (ii)&#160;the Covered Stockholder shall not be required to make any representations and warranties except those that relate solely to the Covered Stockholder and (iii)&#160;the Covered Stockholder shall not be required to undertake any indemnity obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any other provision of this section, the Corporation may, in lieu of allowing the Covered Stockholder to participate in a Public Offering in fulfillment of its rights under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.01(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, offer instead to issue and sell to the Covered Stockholder up to a number of New Securities equal to the Covered Stockholder&#8217;s Pro Rata Share of the New Securities issued in such Public Offering in a concurrent private placement on terms reasonably acceptable to both parties and at a price equal to the price at which the New Securities are sold to the public in the Public Offering.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.02.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Approval of the Covered Stockholder Required for Certain Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to any approval by the Board of Directors required by this Certificate of Incorporation, the Bylaws, applicable laws and regulations or Nasdaq Stock Market, the prior written approval of the Covered Stockholder shall be required in order for the Corporation to take, or the Board of Directors to approve, authorize or effect, any of the following (including by merger, consolidation or otherwise)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the creation (by reclassification or otherwise) or issuance of any new class or series of shares of capital stock of the Corporation (or securities convertible into or exercisable for shares of capital stock of the Corporation) having rights, preferences or privileges senior to or on parity with the Common Stock&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any action to repurchase, retire, redeem or otherwise acquire any equity securities (or securities convertible into or exchangeable for equity securities) of the Corporation or any subsidiary of the Corporation, pursuant to self-tender offers, stock repurchase programs, open market transactions, privately-negotiated purchases or similar transactions&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that no consent of the Covered Stockholder pursuant to this section shall be required in connection with the repurchase, retirement, redemption or other acquisition by the Corporation of securities issued or issuable upon any exercise of options or vesting or exercise of any other equity-based award, in each case under the Corporation&#8217;s equity incentive plans or any other plan or agreement approved by the Board of Directors, to pay the applicable exercise price or taxes associated with such awards&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;take any action to adopt, or propose to adopt, or maintain any shareholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement, unless the Covered Stockholder is exempt from the provisions of such shareholders&#8217; rights plan, &#8220;poison pill&#8221; or other similar plan or agreement&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any authorization of, or entering into an agreement for, or the commitment to agree to take, any of the foregoing actions.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For purposes of this Article XII&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means a person that is the beneficial owner of 20% or more of the Corporation&#8217;s outstanding Common Stock as reflected in the person&#8217;s most recent filings under section 13 of the Securities Exchange Act of 1934, as amended, and that continues to be the beneficial owner of more than 20% of the Corporation&#8217;s Common Stock immediately prior to the time of the transaction or event to which the Covered Stockholder is entitled to rights under this Article XII&#59; provided that for a person to be considered a &#8220;Covered Stockholder,&#8221; such person must send a written notice to the Corporation at its corporate offices, which notice must contain the number of shares of Common Stock beneficially owned by such person and the notice information, which must include a valid email address, at which such person may be reached for purposes of this Article XII. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any capital stock of the Corporation, whether now authorized or not, and rights, options or warrants to purchase such capital stock, and securities of any type whatsoever (including convertible debt securities) that are, or may become, convertible into or exchangeable or exercisable for capital stock of the Corporation&#59;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the term &#8220;New Securities&#8221; does not include (a)&#160;Common Stock or rights, options or warrants to acquire Common Stock of the Corporation issued to employees, consultants, officers or directors of the Corporation or any Subsidiary, or which have been reserved for issuance, pursuant to an employee stock option, stock purchase, stock bonus plan, or other similar compensation plan or arrangement approved by the Board of Directors, (b)&#160;securities of the Corporation issued to all then-existing stockholders in connection with any stock split, stock dividend, reclassification or recapitalization of the Corporation, (c) securities of the Corporation issued upon the conversion or exercise of exchangeable or convertible securities of the Corporation, including warrants and convertible notes, that are (i) outstanding as of the date of this Certificate of Incorporation of the Corporation or (ii) issued subsequently after receipt of the consent of the Covered Stockholder pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (d) securities of the Corporation issued as consideration in the acquisition of business or assets of another person, (e) Common Stock not otherwise contemplated by the foregoing clauses (a) through (d) issued in a given fiscal year pursuant to an &#8220;at the market&#8221; offering in an amount that does not exceed, in the aggregate, 2% of the outstanding Common Stock of the Corporation calculated as of the end of the preceding fiscal year, and (g)&#160;securities of the Corporation issued in connection with a transaction of the type described in Rule&#160;145 under the Securities Act of 1933, as amended. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means an underwritten public offering of New Securities that is registered under the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, this Sixth Amended and Restated Certificate of Incorporation has been executed for and on behalf and in the name of the Corporation by its officers thereunto duly authorized on May 10, 2024.</font></div><div style="margin-bottom:12pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LEXICON PHARMACEUTICALS, INC.</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:256.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lonnel Coats</font></div><div style="margin-bottom:30pt;padding-left:256.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="margin-bottom:24pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attest&#58;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:256.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian T. Crum</font></div><div style="padding-left:256.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secretary</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lxrx-20240510.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:91339ed7-c34d-4130-91e5-d6460f07f312,g:e06e91d0-3e8e-4e3e-af2a-9ce6cb89d8b6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20240510" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20240510">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20240510_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20240510_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.lexpharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lxrx-20240510_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:91339ed7-c34d-4130-91e5-d6460f07f312,g:e06e91d0-3e8e-4e3e-af2a-9ce6cb89d8b6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_ff81b34d-7bb2-4fc4-a452-14c9ebdc7781_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a8377a4f-4736-4b15-8fee-2bd2c3e4e312_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a25b4b4c-e21d-4975-9fb9-48cf02141a39_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8a68d956-c66b-4e8d-9994-3c0ae9066d36_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_894ad7ad-7f9e-4dd3-b9b9-90b2800db660_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_82047b1b-f214-4362-8dd7-c35efb57186f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_88d7005f-1fea-4283-8ee7-01ff3eaa3754_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_18ea4036-9245-4944-84fa-204648049941_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_32a277ac-6775-4d01-81f9-03f0f3e5e2ab_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_85e574d7-36c1-411e-971b-01659744ca2f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_659bfaa4-fbaa-4909-b4d4-c56c7265d696_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_ed0f1d1d-2100-4265-a8c7-756a2b0c573c_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c38105d2-dc6f-4cb2-808b-143a5c093a02_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cdceb00e-0ad8-426e-9d9c-294d9e04464e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7fe67598-365d-421f-8157-bc67e94b2921_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5a3317b0-fcca-4ec9-89f6-2c2183ac29bf_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_00923275-e64f-498d-8ecd-b28d4fa48bc9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_14ad14a0-e95b-433f-9c4e-8b16c76cf4df_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_da805a4b-0c69-4fa8-9e31-22c844396227_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0c73ab2a-e977-4628-82f1-8a9196b6b708_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_afd6102e-ae17-447f-b4a7-d8550297a7fb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1d9b22b4-607e-4b8c-83a0-4c3786bf04a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_971b32c2-fbb7-4de1-a551-d389e8aecb40_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lxrx-20240510_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:91339ed7-c34d-4130-91e5-d6460f07f312,g:e06e91d0-3e8e-4e3e-af2a-9ce6cb89d8b6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20240510.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b3b2e896-dfab-42ad-9f82-274614778af5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_DocumentType_b3b2e896-dfab-42ad-9f82-274614778af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a50cc1e3-4eb9-4c40-a501-5f17b8fd9b8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_DocumentPeriodEndDate_a50cc1e3-4eb9-4c40-a501-5f17b8fd9b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_77799ad1-3c8d-4aa3-ac5f-d328c80a9e1c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityRegistrantName_77799ad1-3c8d-4aa3-ac5f-d328c80a9e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ef6859dd-4066-4b44-b3f5-3f107d5c30ce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ef6859dd-4066-4b44-b3f5-3f107d5c30ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_07bb8d1a-9fb8-4d14-8015-e1cee06a1b79" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityFileNumber_07bb8d1a-9fb8-4d14-8015-e1cee06a1b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_96505add-0326-419c-b3ec-0f72db983621" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityTaxIdentificationNumber_96505add-0326-419c-b3ec-0f72db983621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a22f444e-9775-4f11-8213-17c7e6301bbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityAddressAddressLine1_a22f444e-9775-4f11-8213-17c7e6301bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f59f27de-eca5-4567-9f0b-8c8cd9e2bffb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityAddressCityOrTown_f59f27de-eca5-4567-9f0b-8c8cd9e2bffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a9951134-8260-4d3a-a217-a892393e52b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityAddressStateOrProvince_a9951134-8260-4d3a-a217-a892393e52b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fdb067dd-2312-4c90-ab72-b597913cf2ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityAddressPostalZipCode_fdb067dd-2312-4c90-ab72-b597913cf2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f99cbc00-a58a-4e69-acbb-c2add57277c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_CityAreaCode_f99cbc00-a58a-4e69-acbb-c2add57277c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6e653c1d-5ae4-4677-92dd-2c43289bbb13" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_LocalPhoneNumber_6e653c1d-5ae4-4677-92dd-2c43289bbb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1f819288-67cb-4ebe-ac7c-76286bf781b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_Security12bTitle_1f819288-67cb-4ebe-ac7c-76286bf781b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9527db91-a931-452d-9463-fcb2335f2064" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_TradingSymbol_9527db91-a931-452d-9463-fcb2335f2064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_920877ce-18b5-41cd-89a8-bc72e7b3eba2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_SecurityExchangeName_920877ce-18b5-41cd-89a8-bc72e7b3eba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_50989e9d-11fc-4b58-9e17-d3d741aea85f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_WrittenCommunications_50989e9d-11fc-4b58-9e17-d3d741aea85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_3f029e3b-50e6-4566-b765-1a5180c8be71" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_SolicitingMaterial_3f029e3b-50e6-4566-b765-1a5180c8be71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0831b117-2eac-4f6a-b04c-79e2423222c1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_PreCommencementTenderOffer_0831b117-2eac-4f6a-b04c-79e2423222c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_0cd89991-dfb3-4b67-a61b-d80316816114" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_0cd89991-dfb3-4b67-a61b-d80316816114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b12f0bf6-ef5a-4218-9959-f5279e2f13b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityEmergingGrowthCompany_b12f0bf6-ef5a-4218-9959-f5279e2f13b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_62385374-e80f-4858-b34a-16315d9b18ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_EntityCentralIndexKey_62385374-e80f-4858-b34a-16315d9b18ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b0e0c6e5-680e-477f-b55d-d48544adf638" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_AmendmentFlag_b0e0c6e5-680e-477f-b55d-d48544adf638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dcff5e7e-5ec4-4a17-9342-12d0a52f37fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c2322a0a-ba65-47fa-a6c7-cf6ad9aa9173" xlink:to="loc_dei_CurrentFiscalYearEndDate_dcff5e7e-5ec4-4a17-9342-12d0a52f37fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140400777429808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 10, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 10,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd., 11th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#7!"VJS,C(:[ N+,:*+67 ]< U+V@AL<PF[W8?Z)L&>V(]2[(+[G=_X?[0)
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M<F]P<R]A<' N>&UL4$L! A0#%     @ ^H&J6"!Q\2KN    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ^H&J
M6)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #Z@:I8WDVW(VX$   N$0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ^H&J
M6)^@&_"Q @  X@P   T              ( !L0P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #Z@:I8EXJ[',     3 @  "P              @ &-#P
M7W)E;',O+G)E;'-02P$"% ,4    " #Z@:I8JL0B%C,!   B @  #P
M        @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ^H&J6"0>
MFZ*M    ^ $  !H              ( !UA$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ ^H&J6&60>9(9 0  SP,  !,
M     ( !NQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&!10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lxrx-20240510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="lxrx-20240510.htm">lxrx-20240510.htm</File>
    <File>lxrx-20240510.xsd</File>
    <File>lxrx-20240510_lab.xml</File>
    <File>lxrx-20240510_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lxrx-20240510.htm": {
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20240510",
   "dts": {
    "inline": {
     "local": [
      "lxrx-20240510.htm"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20240510.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20240510_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20240510_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.lexpharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20240510.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lxrx-20240510.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001062822-24-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-24-000029-xbrl.zip
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M,7O_.?%N3T\>[*K=&^T/.6D_U*-?X2(V$0<,@"0E:>RD?B<K @Y(FOA<BV]
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MS=6"HSDF5D,1?8DM21@JJ.>8ADY1)TM$Z/( 5LMX(FY )$P9E :#T?H4 O>
M94.)>XCW.LLS[P/#(.XCIO68_ P%_;=DIPS/L_<E*K*Q%08OW'8FQ\'6Q4P
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MML1%CO@ZT3W\F74/D5O.808/F)_Y75::YA>@3NA;]++.M"IKUG@"0BF&UF@
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M?B$W#_.N+!/=W_#.?O-Q<+WN-4,7=ZN$%U_:]*KU]@)6G/0YT=L[(H?C51T
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M%'BU%GD]F=(R'$9%2;'I<5)&<%4NM"K:4DU$O]P&'!&RODL?UF(39HD5[*6
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MO;T87N0FK^@?"XHE;%><9M5L5YS V;>'9YMT!F]0_TF!U52U;L_I)T<=3GF
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MSLB>!$6I=&G6EAT66I/I4LL[$_+QPX.\,;\]_9G/]933,$DX20%)PA@0@2)
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ME5%I!'@4(:!"RC3E6@IB_?<$N@3&@?%9T_%O0G76Q)8^?Z=>X-F:],"MV\D
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M4$L! A0#%     @ ^H&J6/5F$H2Q,0  0&\! !X              ( !
M &5X:#,Q+7-I>'1H86UE;F1E9&%N9')E<W1A+FAT;5!+ 0(4 Q0    ( /J!
MJEB3/ )N)Q0  +>;   1              "  >TQ  !L>')X+3(P,C0P-3$P
M+FAT;5!+ 0(4 Q0    ( /J!JEA^Y[2S;0(  ','   1              "
M 4-&  !L>')X+3(P,C0P-3$P+GAS9%!+ 0(4 Q0    ( /J!JEBW9;)S80H
M  18   5              "  =](  !L>')X+3(P,C0P-3$P7VQA8BYX;6Q0
M2P$"% ,4    " #Z@:I8F'\TTN$&  #W,@  %0              @ %S4P
K;'AR>"TR,#(T,#4Q,%]P<F4N>&UL4$L%!@     %  4 4 $  (=:      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>lxrx-20240510_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20240510.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-23">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-05-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2445 Technology Forest Blvd., 11th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
